Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America
Gilead Sciences, Inc. today announced its partnership with IAS - the International AIDS Society - to expand the Me & My Healthcare Provider campaign to three locations in Asia...
October 13, 2021
by prnasia
Gilead Sciences to acquire MYR GmbH
Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing of transaction.
December 11, 2020
by expresspharma
Gilead Sciences, AIDS Society of India survey highlights disruption in HIV care during COVID-19
Gilead Sciences and the AIDS Society of India announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on access and delivery of HIV care in the Asia Pacific.
December 1, 2020
by expresspharma
Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic
Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, in Asia Pacific.
November 30, 2020
by prnasia
Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program
Gilead Sciences, Inc. today announced the recipients of its first Asia HIV Research Scholar Program. The Program awards up to US$130,000 over a period of two years to support innovative HIV scientific research led by early-career researchers from ...
November 16, 2020
by prnasia
Gilead Sciences acquires Immunomedics in $21bn deal
Gilead Sciences has completed the previously announced acquisition of cancer therapies developer Immunomedics for approximately $21bn.
October 28, 2020
by pharmaceutical-technology
Gilead Sciences Signs Agreement with Jounce Therapeutics
Gilead Sciences Inc. has signed an agreement with Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.
September 3, 2020
by contractpharma
Dr Reddy’s signs licensing agreement with Gilead Sciences for remdesivir
Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug and needs to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.
June 15, 2020
by expresspharma
Health groups ask India to rescind Gilead’s patents for COVID-19 drug remdesivir
Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.
May 15, 2020
by expresspharma
Gilead announces primary endpoints met in Phase III remdesivir trial
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
April 30, 2020
by europeanpharmaceuticalreview
Gilead supersizes remdesivir trials, changes primary endpoint
Gilead Sciences has made major mid-study changes to its global remdesivir trials, quadrupling the enrollment target and switching the primary endpoint.
April 10, 2020
by fiercebiotech
Gilead signs drug discovery deal with Second Genome
Gilead Sciences has entered a multi-programme agreement with Second Genome to discover targets and drug candidates for inflammatory bowel disease (IBD) treatment.
April 8, 2020
by pharmaceutical-technology